Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients

Autores
Perez Lloret, Santiago; Rey, María Verónica; Crispo, James; Krewski, Daniel; Lapeyre Mestre, Marise; Montastruc, Jean Louis; Rascol, Olivier
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson’s disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced dyskinesias. However, their utilization is limited by the risk of adverse drug reactions, some of which affect the cardiovascular system. Recently, the US FDA identified a possible association between exposure to pramipexole and the risk of heart failure. Areas covered: This article begins by reviewing the pharmacodynamic and cardiovascular effects of DAs on PD patients. Pharmacoepidemiological studies about the association between DAs and heart failure are then evaluated. Expert opinion: Four nested case-control studies were reviewed. In general, results showed higher heart failure risk following use of pramipexole or cabergoline. Although the effects of cabergoline may be explained by the induction of cardiac valve fibrosis, the basis for the significantly increased risk associated with pramipexole is unclear. It remains to be determined if these are dose-related effects, at what point they occur during the course of treatment, and if the risk is the same for all patients irrespective of other potential modifying factors, such as age and sex.
Fil: Perez Lloret, Santiago. Inserm; Francia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universitá Paul Sabatier; Francia
Fil: Rey, María Verónica. Inserm; Francia. Universitá Paul Sabatier; Francia
Fil: Crispo, James. University of Ottawa; Canadá
Fil: Krewski, Daniel. University of Ottawa; Canadá
Fil: Lapeyre Mestre, Marise. Inserm; Francia. Universitá Paul Sabatier; Francia
Fil: Montastruc, Jean Louis. Inserm; Francia. Universitá Paul Sabatier; Francia
Fil: Rascol, Olivier. Inserm; Francia. Universitá Paul Sabatier; Francia
Materia
Adverse Drug Reactions
Cardiovascular Events
Dopamine Agonists
Heart Filure
Parkinson'S Disease
Pharmacovigilnace
Pramipexole
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/16097
Acceder
id CONICETDig_6a40f86ba24a04ed3c6ab9978f4c382d
oai_identifier_str oai:ri.conicet.gov.ar:11336/16097
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patientsPerez Lloret, SantiagoRey, María VerónicaCrispo, JamesKrewski, DanielLapeyre Mestre, MariseMontastruc, Jean LouisRascol, OlivierAdverse Drug ReactionsCardiovascular EventsDopamine AgonistsHeart FilureParkinson'S DiseasePharmacovigilnacePramipexolehttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson’s disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced dyskinesias. However, their utilization is limited by the risk of adverse drug reactions, some of which affect the cardiovascular system. Recently, the US FDA identified a possible association between exposure to pramipexole and the risk of heart failure. Areas covered: This article begins by reviewing the pharmacodynamic and cardiovascular effects of DAs on PD patients. Pharmacoepidemiological studies about the association between DAs and heart failure are then evaluated. Expert opinion: Four nested case-control studies were reviewed. In general, results showed higher heart failure risk following use of pramipexole or cabergoline. Although the effects of cabergoline may be explained by the induction of cardiac valve fibrosis, the basis for the significantly increased risk associated with pramipexole is unclear. It remains to be determined if these are dose-related effects, at what point they occur during the course of treatment, and if the risk is the same for all patients irrespective of other potential modifying factors, such as age and sex.Fil: Perez Lloret, Santiago. Inserm; Francia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universitá Paul Sabatier; FranciaFil: Rey, María Verónica. Inserm; Francia. Universitá Paul Sabatier; FranciaFil: Crispo, James. University of Ottawa; CanadáFil: Krewski, Daniel. University of Ottawa; CanadáFil: Lapeyre Mestre, Marise. Inserm; Francia. Universitá Paul Sabatier; FranciaFil: Montastruc, Jean Louis. Inserm; Francia. Universitá Paul Sabatier; FranciaFil: Rascol, Olivier. Inserm; Francia. Universitá Paul Sabatier; FranciaTaylor & Francis2014-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/16097Perez Lloret, Santiago; Rey, María Verónica; Crispo, James; Krewski, Daniel; Lapeyre Mestre, Marise; et al.; Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients; Taylor & Francis; Expert Opinion On Drug Safety; 13; 3; 3-2014; 351-3601474-03381744-764Xenginfo:eu-repo/semantics/altIdentifier/doi/10.1517/14740338.2014.888057info:eu-repo/semantics/altIdentifier/url/http://www.tandfonline.com/doi/full/10.1517/14740338.2014.888057info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:38:42Zoai:ri.conicet.gov.ar:11336/16097instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:38:42.36CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
title Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
spellingShingle Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
Perez Lloret, Santiago
Adverse Drug Reactions
Cardiovascular Events
Dopamine Agonists
Heart Filure
Parkinson'S Disease
Pharmacovigilnace
Pramipexole
title_short Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
title_full Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
title_fullStr Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
title_full_unstemmed Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
title_sort Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
dc.creator.none.fl_str_mv Perez Lloret, Santiago
Rey, María Verónica
Crispo, James
Krewski, Daniel
Lapeyre Mestre, Marise
Montastruc, Jean Louis
Rascol, Olivier
author Perez Lloret, Santiago
author_facet Perez Lloret, Santiago
Rey, María Verónica
Crispo, James
Krewski, Daniel
Lapeyre Mestre, Marise
Montastruc, Jean Louis
Rascol, Olivier
author_role author
author2 Rey, María Verónica
Crispo, James
Krewski, Daniel
Lapeyre Mestre, Marise
Montastruc, Jean Louis
Rascol, Olivier
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Adverse Drug Reactions
Cardiovascular Events
Dopamine Agonists
Heart Filure
Parkinson'S Disease
Pharmacovigilnace
Pramipexole
topic Adverse Drug Reactions
Cardiovascular Events
Dopamine Agonists
Heart Filure
Parkinson'S Disease
Pharmacovigilnace
Pramipexole
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson’s disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced dyskinesias. However, their utilization is limited by the risk of adverse drug reactions, some of which affect the cardiovascular system. Recently, the US FDA identified a possible association between exposure to pramipexole and the risk of heart failure. Areas covered: This article begins by reviewing the pharmacodynamic and cardiovascular effects of DAs on PD patients. Pharmacoepidemiological studies about the association between DAs and heart failure are then evaluated. Expert opinion: Four nested case-control studies were reviewed. In general, results showed higher heart failure risk following use of pramipexole or cabergoline. Although the effects of cabergoline may be explained by the induction of cardiac valve fibrosis, the basis for the significantly increased risk associated with pramipexole is unclear. It remains to be determined if these are dose-related effects, at what point they occur during the course of treatment, and if the risk is the same for all patients irrespective of other potential modifying factors, such as age and sex.
Fil: Perez Lloret, Santiago. Inserm; Francia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universitá Paul Sabatier; Francia
Fil: Rey, María Verónica. Inserm; Francia. Universitá Paul Sabatier; Francia
Fil: Crispo, James. University of Ottawa; Canadá
Fil: Krewski, Daniel. University of Ottawa; Canadá
Fil: Lapeyre Mestre, Marise. Inserm; Francia. Universitá Paul Sabatier; Francia
Fil: Montastruc, Jean Louis. Inserm; Francia. Universitá Paul Sabatier; Francia
Fil: Rascol, Olivier. Inserm; Francia. Universitá Paul Sabatier; Francia
description Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson’s disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced dyskinesias. However, their utilization is limited by the risk of adverse drug reactions, some of which affect the cardiovascular system. Recently, the US FDA identified a possible association between exposure to pramipexole and the risk of heart failure. Areas covered: This article begins by reviewing the pharmacodynamic and cardiovascular effects of DAs on PD patients. Pharmacoepidemiological studies about the association between DAs and heart failure are then evaluated. Expert opinion: Four nested case-control studies were reviewed. In general, results showed higher heart failure risk following use of pramipexole or cabergoline. Although the effects of cabergoline may be explained by the induction of cardiac valve fibrosis, the basis for the significantly increased risk associated with pramipexole is unclear. It remains to be determined if these are dose-related effects, at what point they occur during the course of treatment, and if the risk is the same for all patients irrespective of other potential modifying factors, such as age and sex.
publishDate 2014
dc.date.none.fl_str_mv 2014-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/16097
Perez Lloret, Santiago; Rey, María Verónica; Crispo, James; Krewski, Daniel; Lapeyre Mestre, Marise; et al.; Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients; Taylor & Francis; Expert Opinion On Drug Safety; 13; 3; 3-2014; 351-360
1474-0338
1744-764X
url http://hdl.handle.net/11336/16097
identifier_str_mv Perez Lloret, Santiago; Rey, María Verónica; Crispo, James; Krewski, Daniel; Lapeyre Mestre, Marise; et al.; Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients; Taylor & Francis; Expert Opinion On Drug Safety; 13; 3; 3-2014; 351-360
1474-0338
1744-764X
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1517/14740338.2014.888057
info:eu-repo/semantics/altIdentifier/url/http://www.tandfonline.com/doi/full/10.1517/14740338.2014.888057
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613223655931904
score 13.070432

Publicaciones similares